MEET THE CML MILESTONES THAT MATTER

This is a simplified way to understand chronic myeloid leukemia (CML) treatment milestones. Think of the dots shown in the body as the amount of leukemic cells in the blood. With each treatment milestone, the amount of leukemia in the body is reduced.



AT DIAGNOSIS

The level of BCR-ABL in the body is different for every patient at diagnosis, as measured on the International Scale (IS).[1]

EARLY MOLECULAR RESPONSE (EMR)

An early molecular response means that the BCR-ABL gene is ≤10% when measured on the International Scale (IS).[1]

COMPLETE CYTOGENETIC RESPONSE (CCyR)

A complete cytogenetic response means that the BCR-ABL gene is ≤1% when measured on the International Scale (IS).[1]

MAJOR MOLECULAR RESPONSE (MMR)

An MMR (or molecular response of 3.0) means that the BCR-ABL gene is ≤0.1% when measured on the International Scale (IS).[1]

MR4.5: DEEPER RESPONSE

An MR4.5 means BCR-ABL ≤0.0032% when measured on the International Scale (IS). It also means that amount of leukemic cells is extremely low or nearly undetectable by the most sensitive testing methods. No patients who achieved MR4.5 progressed to advanced stages of the disease in clinical trials, but not all patients may reach this milestone and some patients may reach goals earlier than others. [1,2,3]

NOVARTIS ONCOLOGY

Novartis Pharma AG
CH-4002 Basel Switzerland
© Novartis 2015
9/15 G-CML-1124287

References::
1. Hehlmann R, et al. J Clin Oncol. 2014;32(5):415-423.
2. Kantarjian HM, et al. Lancet Oncol. 2011;12(9)841-851.
3. Kantarjian HM, et al. Blood. 2012;119(5):1123-1129.